STOCKRETAIL-DRUG STORES AND PROPRIETARY STORESUpdated 2026-04-19
Here’s whether CVS HEALTH CORPORATION (CVS) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +12.8%. Concerns: RSI 72 — overbought, elevated pullback risk. Currently 9.2% off its 52-week high. Score: +3/7.
CVS is in a confirmed uptrend, trading above both its 50-day ($76.05) and 200-day ($74.90) moving averages. With an RSI of 72.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +12.8% compares to +35.1% for SPY (trailed the market by 22.3%).
$10,000 invested 1 year ago→ $11,276 today
vs. S&P 500 (SPY) — same period trailed market by 22.3%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($74.90)
✓Above 50-day MA ($76.05)
!RSI(14) neutral zone (30–70) — currently 72.1
✓Positive return (+12.8%)
✓Within 10% of period high (−9.2%)
Period Range $77.30
$58.35$85.15
RSI (14) 72.1
0 · OversoldOverbought · 100
Key Metrics
Price$77.30
Period Return+12.8%
Period High$85.15
Period Low$58.35
Drawdown−9.2%
MA-50$76.05
MA-200$74.90
RSI (14)72.1
Avg Volume (30d)7.5M
vs. SPYtrailed by 22.3%
Return Rank#599 of 996
Trend Signals
Price is above the 200-day moving average ($74.90)